SUVENSuven Life Sciences Limited
Convert to ideaHealthcare · Healthcare Services
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.4 this quarter.
Momentum from moving averages, Supertrend and RSI.
6 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
6 found · risk severe
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹1 Cr | ₹-107 Cr | -100.00% | -8911.67% | ₹-3.77 | -50.0x |
| Q1 FY2027 | ₹4 Cr | ₹-128 Cr | -100.00% | -3574.51% | ₹-4.84 | -50.0x |
| Q4 FY2026 | ₹2 Cr | ₹-46 Cr | -100.00% | -2999.34% | ₹-2.02 | -50.0x |
| Q3 FY2026 | ₹3 Cr | ₹-102 Cr | -100.00% | -3640.00% | ₹-4.55 | N/A |
| Q2 FY2026 | ₹1 Cr | ₹-77 Cr | -100.00% | -8494.51% | ₹-3.48 | N/A |
| Q1 FY2026 | ₹2 Cr | ₹-52 Cr | -100.00% | -2769.35% | ₹-2.36 | N/A |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Healthcare Services
Compare with peers →Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.